TERN Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of --. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Cogent Biosciences, Inc.'s return on equity of -104.81%.

Terns Pharmaceuticals, Inc. has a consensus price target of $58.11, signalling upside risk potential of 38.26%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $53.83 which suggests that it could grow by 38.43%. Given that Cogent Biosciences, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of -0.305, which suggesting that the stock is 130.486% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.231%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Cogent Biosciences, Inc.'s net income of -$102.5M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 11.83%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.

Terns Pharmaceuticals, Inc. has a consensus price target of $58.11, signalling upside risk potential of 38.26%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $65.40 which suggests that it could grow by 81.82%. Given that Corcept Therapeutics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of -0.305, which suggesting that the stock is 130.486% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.236%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 43.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 5.66x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of -124.5%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Insmed, Inc.'s return on equity of -192.35%.

Terns Pharmaceuticals, Inc. has a consensus price target of $58.11, signalling upside risk potential of 38.26%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 45.25%. Given that Insmed, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Terns Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of -0.305, which suggesting that the stock is 130.486% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.131, suggesting its more volatile than the S&P 500 by 13.112%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 47.99x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 75.06%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Ligand Pharmaceuticals, Inc.'s return on equity of 14.07%.

Terns Pharmaceuticals, Inc. has a consensus price target of $58.11, signalling upside risk potential of 38.26%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $244.56 which suggests that it could grow by 20.74%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Ligand Pharmaceuticals, Inc..

Terns Pharmaceuticals, Inc. has a beta of -0.305, which suggesting that the stock is 130.486% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.207, suggesting its more volatile than the S&P 500 by 20.687%.

Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $59.7M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Ligand Pharmaceuticals, Inc.'s net income of $44.8M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 34.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 15.28x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.